Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (1896)	9/25/2007 1:07:55 PM
From: Robohogs	Respond to of 3722

Also add in MYGN. Jon

To: Steve Lokness who wrote (1896)	9/25/2007 11:20:29 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

Steve, TWTI Also has been on a near term UT since July 24 when it had the spike on volume of 2,926,200 after it announced that the U.S. District Court in Wisconsin issued a patent opinion in its favor on the claim dispute it had with Digine. That UT has been preserved (the intraday break on Aug 14 doesn't count since it recovered well of the "panic selling". bigcharts.marketwatch.com There has been some insider buying in spite of the higher losses in the first 2Qs.( The EL for 2007 is around $0.60/shr vs. $0.42/shr in 2006 ) But revenues on the 2ndQ were a little better & the EL is less than it was a few weeks ago) This week the stock made a 5 Yrs H as it traded above its Dec 2004 H of $9.08 The all time H was $11.65 in June 2001 bigcharts.marketwatch.com CPHD's UT started on March 14 from the $8.50 level after it filed its annual report. The agreement with ABT last September, the purchase of Sangtec in Feb, the presentation at the AACC in July,the announcement in Aug of the purchase order for $200M of anthrax test cartridges for use on the BDS at the UPS & the fact that it has continued to trim its losses has helped it to keep the UT.(Also remember my comments back in April on the FDA approval of its test for MRSA.) Message 23469945 bigcharts.marketwatch.com It is due to present tomorrow at the UBS conference in NY & it will probably be able to go over last Wednesday H. GHDX Had an UT last Yr. from June to Dec (from the 10.90 to the 24.30 level. After the double top in Jan it retraced to the 14.75 level on May 18 It rallied from there up to the 22.25 on July 19, but it has been on a near term DT since then. It needs to close above the 21 level.Support is at 18.75 bigcharts.marketwatch.com It presented some posters at the ASCO Breast Cancer Symposium in Frisco earlier this month & also last week in Frisco the CEO presented at the ThinkEquity Partners 5th Growth Conference. It hasn't been able to cut its loss in spite of significant better revenues, but things are expected to get better in the pending 2 Qs for this Yr. & for 2008 the loss is expected to be cut by at least 75%. Bernard

To: Steve Lokness who wrote (1896)	9/25/2007 11:36:30 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

Ah, heck, throw in ILMN too? How about LMRA ? <g> bigcharts.marketwatch.com Plexera Bioscience and MitoSciences Inc. Announce Collaboration on Mitochondrial Array Tuesday September 25, 8:45 am ET Letter of Intent Outlines Commercial Path for Mitochondrial Antibody Arrays for Use on the ProteomicProcessor(TM) BOTHELL, Wash.--(BUSINESS WIRE)--Plexera Bioscience LLC, a wholly owned subsidiary of Lumera Corporation (NASDAQ:LMRA - News), and MitoSciences Inc., developers of antibodies and assays for understanding mitochondrial function, announced today that they have entered into an agreement that outlines a commercial path for an antibody array product which is enabled with Plexera's ProteomicProcessor(TM) and MitoSciences' proprietary antibodies. This product development is in conjunction with a separate and previously announced agreement with the Medical University of South Carolina in which researchers there are building a protein expression profiling assay with Mitosciences' antibodies and Plexera's ProteomicProcessor(TM). "Changes in mitochondrial proteins are known to be markers for certain pathologies and many adverse drug effects. We feel that by combining MitoSciences' well characterized antibodies and Plexera's ProteomicProcessor(TM) we will have an assay that will have significant time and cost advantages over existing technologies. Perhaps as important will be our ability to identify and characterize multiple protein markers in one assay," said Dr. Craig Beeson, Associate Professor of Pharmaceutical Sciences at MUSC and the Principle Investigator on this project. "We are excited to be working along side of MitoSciences and believe that combining their content with our detection platform has very exciting commercial prospects," said Dr. Tim Londergan, President and Chief Operating Officer of Plexera. "This has the potential to become a mainstream assay in the ADME and toxicology market as pharmaceutical companies desperately need to find new ways to screen and eliminate problematic compounds sooner in the process." The total U.S. ADME/Tox market was estimated to be $1.1 billion in 2003 and is expected to grow to $2.8 billion by 2009, representing a compound annual growth rate of 17.2%. Failures of pipeline drugs due to ADME and toxicology are estimated to be in the 50% to 60% range, making it the number one reason for preclinical attrition, according to market research firm Business Insights, Ltd. High-throughout technologies that quickly and efficiently identify toxic drug compounds promise to increase the success rate of new pharmaceutical drug development. "This agreement is the first step in what we hope to be a long and prosperous commercial relationship with Plexera. Plexera's interest in accessing our proprietary antibody library for use with the ProteomicProcessor(TM) further validates the market's demand for more advanced mitochondrial related assays," said John Audette, President of MitoSciences. Snip Bernard

To: Steve Lokness who wrote (1896)	2/13/2008 11:44:12 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CBMX opened with an UG & is trading above its March 2007 H after it announced that it has been awarded $31.4M by a Federal Court in its lawsuit against National Union Fire Ins. bigcharts.marketwatch.com But the price is still far from its Feb 2007 spike.<g> In Feb 2007 at the time it raised $52M in an IPO. it said that it had developed a system for the creation of DNA and other compounds on a programmable semiconductor chip.(that was in spite of losing $15.5M on revenue of $4.8M during the first 9 months of the year & previous loss of about $140M during its history, & it warned that it "may never become profitable." <g> So far the company has continued to accumulate heavy losses. Will see what it will be able to do with the $31M. <g> bigcharts.marketwatch.com Bernard

To: Steve Lokness who wrote (1896)	2/26/2008 3:56:53 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

TWTI has been up 14.63% & is still up 11.53% on volume of 340,325 which is > its ADV but wasn't able to test its Feb 21 H at $8.50 <g> bigcharts.marketwatch.com It reported its 4thQ results, which showed 31% better revenues, but a higher loss. The loss for the Yr. was $0.65/shr vs. the $0.45/shr in 2006. For 2008 the EL is around $0.45 & for 2009 it is expected to be down around $0.20/shr TWTI cash & equivalents at the end of the Yr was $35.7M vs. $44.2M in 2006. It also obtained a 5 Yrs $25M unsecured letter of credit in the 4thQ. The stock is trying to get off from the DT coming from its Jan 2 H at $9.70 & still would have further resistance from the Oct 29 H at $9.89 The May 2001 H was $11.65 bigcharts.marketwatch.com Bernard